Research published in April in the Journal of the National Comprehensive Cancer Network showcases the feasibility of improving early detection and prevention for pancreatic cancer.
The College of American Pathologists in collaboration with the International Association for the Study of Lung Cancer, Pulmonary Pathology Society, Association for Molecular Pathology, and the LUNGevity Foundation have developed evidence-based recommendations for the testing of immunotherapy biomarkers, including programmed cell death ligand-1 and tumor mutation burden in patients with non-small cell lung carcinoma.
A urine test that measures 18 genes associated with prostate cancer provides higher accuracy for detecting clinically significant cancers than PSA and other existing biomarker tests, according to a study published April 18 in JAMA Oncology.
Genentech’s phase III STARGLO study met its primary endpoint of overall survival.
Research from the University of Pittsburgh explains why metastatic uveal melanoma is resistant to conventional immunotherapies and how adoptive therapy, which involves growing a patient’s T cells outside the body before reinfusing them, can successfully treat this rare and aggressive cancer.
Data from a subset of patients in an ongoing phase I study of Poseida Therapeutics’s lead program P-BCMA-ALLO1 showed that three of the five (60%) patients with relapsed/refractory multiple myeloma who had progressed following BCMA-targeted therapy achieved clinical responses with P-BCMA-ALLO1. In addition, this investigational treatment was well-tolerated.
Researchers at MD Anderson Cancer Center showed that altering the sequence of breast cancer treatment to administer radiation before mastectomy allowed for concurrent breast reconstruction surgery, which reduced the number of operations required, minimized treatment delays, and improved patient satisfaction.
In the phase III ADRIATIC trial, Imfinzi (durvalumab) showed a statistically significant and clinically meaningful improvement in overall survival and progression-free survival for patients with limited-stage small cell lung cancer who had not progressed following concurrent chemoradiotherapy, compared to placebo after cCRT.
The phase I/II LINKER-MM1 trial of linvoseltamab in R/R MM produced positive pivotal data in patients with relapsed/refractory multiple myeloma.
Non-classical mutations are present in 20-30% of all patients with epidermal growth factor receptor-mutated non-small cell lung cancer, according to an analysis of real-world evidence presented by Black Diamond Therapeutics, Inc. at the American Association of Cancer Research annual meeting.
